Saxenda 3ml Liraglutide Injection Pen — GLP-1 Weight Management
- GLP-1 receptor agonist — 97% homology with human GLP-1
- Clinically proven: 56% of patients achieve ≥5% weight loss at 56 weeks
- 3ml multi-dose prefilled injection pen (18mg liraglutide)
- 5-step dose escalation: 0.6mg to 3.0mg once daily
- Delays gastric emptying by 31% and enhances satiety
- Improves metabolic markers: HbA1c -0.6%, SBP -2.8mmHg
| 1 - 2 boxes | $135.00 / pen |
| 3 - 9 boxes | $128.25 / pen |
| 10 - 19 boxes | $121.50 / pen |
| 20 - 29 boxes | $117.45 / pen |
| 30+ boxes | Contact for quote |
What Is Saxenda 3ml Liraglutide Injection Pen — GLP-1 Weight Management?
Saxenda (liraglutide 6 mg/ml) — an FDA-approved GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. 3ml multi-dose prefilled injection pen delivers 18mg liraglutide.
Saxenda (liraglutide 6 mg/ml) is a prescription GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions such as hypertension or type 2 diabetes. Clinical trials demonstrate that 56% of patients achieved ≥5% weight loss at 56 weeks when combined with lifestyle modifications. The 3ml pre-filled pen delivers 18mg liraglutide through easy-to-use multidose injections, working as a GLP-1 receptor agonist (97% amino acid sequence homology with human GLP-1) to regulate appetite, delay gastric emptying by 31%, and improve metabolic health markers including HbA1c (−0.6%) and systolic blood pressure (−2.8 mmHg).
Specifications
| Product name | Saxenda 3ml Liraglutide Injection Pen |
|---|---|
| Brand | Novo Nordisk |
| Type | GLP-1 receptor agonist weight management injection |
| Active ingredient | Liraglutide 6 mg/ml (18mg per 3ml pen) |
| Presentation | 3ml multi-dose prefilled injection pen |
| Administration | Subcutaneous injection once daily |
| Dose escalation | Week 1: 0.6mg → Week 2: 1.2mg → Week 3: 1.8mg → Week 4: 2.4mg → Maintenance: 3.0mg daily |
| Treatment | Chronic weight management (BMI ≥30 or BMI ≥27 with comorbidities) |
| Duration | 56-week program (long-term maintenance available) |
| Origin | Denmark (Novo Nordisk) |
| Certification | FDA |
| Storage | Unopened: 2–8°C; In-use: ≤30°C for ≤30 days. Do not freeze. |
Key Benefits
- Significant weight loss — 56% achieve ≥5% weight loss
- Convenient multi-dose pen — one pen covers multiple injections
- Dose escalation protocol minimizes GI intolerance
- Metabolic health improvements beyond weight loss
- FDA-approved for chronic weight management
- Proven safety profile with long-term clinical data
Suggested Treatment Protocol
Saxenda uses a 5-step dose escalation protocol to minimize GI intolerance: Week 1: 0.6mg once daily. Week 2: 1.2mg once daily. Week 3: 1.8mg once daily. Week 4: 2.4mg once daily. Maintenance: 3.0mg once daily (from Week 5 onwards). Administer subcutaneously in the abdomen, thigh, or upper arm at the same time each day. Rotate injection sites. Assess weight loss at 16 weeks; discontinue if less than 4% baseline weight loss has been achieved. Contraindicated in pregnancy, personal/family history of medullary thyroid carcinoma, or multiple endocrine neoplasia type 2.
Frequently Asked Questions
What is Saxenda?
Saxenda (liraglutide) is an FDA-approved GLP-1 receptor agonist for chronic weight management. It works by mimicking the natural GLP-1 hormone to regulate appetite, slow gastric emptying, and promote satiety, helping patients achieve and maintain significant weight loss.
How is Saxenda administered?
Saxenda is administered as a once-daily subcutaneous injection using a multi-dose prefilled pen. Inject in the abdomen, thigh, or upper arm at the same time each day. The 3ml pen delivers 18mg of liraglutide for multiple doses.
What is the dosing schedule?
Saxenda uses a 5-step dose escalation: Week 1: 0.6mg → Week 2: 1.2mg → Week 3: 1.8mg → Week 4: 2.4mg → Maintenance from Week 5 onwards: 3.0mg once daily.
What results can I expect?
Clinical trials show that 56% of patients achieve ≥5% weight loss at 56 weeks when combined with lifestyle changes. Average 8% body weight reduction is observed over 12 months. Saxenda also improves HbA1c by 0.6% and systolic BP by 2.8 mmHg.
How should Saxenda be stored?
Unopened pens should be stored in the refrigerator at 2–8°C. Once in use, the pen can be stored at ≤30°C for up to 30 days. Do not freeze. Protect from light.
What is the difference between Saxenda and Wegovy?
Saxenda (liraglutide) is a once-daily injection with a 5-step dose escalation to 3.0mg, while Wegovy (semaglutide) is a once-weekly injection with a 5-step escalation to 2.4mg. Both are GLP-1 receptor agonists from Novo Nordisk for weight management, but they use different active ingredients and dosing schedules.
Good alternative to once-weekly GLP-1 options. Saxenda's daily dosing can actually improve compliance for some patients as it becomes part of their daily routine. Metabolic improvements are a nice bonus.
Saxenda remains a reliable option for weight management. The once-daily dosing schedule with the multi-dose pen is convenient. Results are predictable when combined with proper dietary counseling.
Solid GLP-1 therapy with proven outcomes. The 56-week clinical data showing 56% achieving ≥5% weight loss is impressive. Easy-to-use pen design and well-established safety profile.
Highly effective medication. The dose escalation from 0.6mg to 3.0mg is well-designed to minimize side effects. Patients appreciate the gradual increase and the metabolic benefits beyond weight loss.
Excellent GLP-1 therapy for weight management. The Saxenda pen is easy for patients to use and the dose escalation protocol is well-tolerated. I have seen consistent 5-8% weight loss in my patients over 6 months.
Please log in to leave a review.